Asad Haider
Stock Analyst at Goldman Sachs
(2.69)
# 1,920
Out of 5,133 analysts
14
Total ratings
66.67%
Success rate
17.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Buy | $213 → $240 | $213.65 | +12.33% | 3 | Dec 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $31.86 | +16.13% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $55.92 | +1.93% | 2 | Dec 2, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $19.51 | -12.87% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $40.36 | +4.06% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $46.02 | -17.43% | 1 | Sep 12, 2025 | |
| BNTX BioNTech SE | Initiates: Neutral | $110 | $107.19 | +2.62% | 1 | May 29, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $1,077.19 | -17.56% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $220.75 | -12.12% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $25.15 | -0.60% | 1 | Apr 8, 2025 |
Johnson & Johnson
Dec 19, 2025
Maintains: Buy
Price Target: $213 → $240
Current: $213.65
Upside: +12.33%
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $31.86
Upside: +16.13%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $55.92
Upside: +1.93%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $19.51
Upside: -12.87%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $40.36
Upside: +4.06%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $46.02
Upside: -17.43%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $107.19
Upside: +2.62%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $1,077.19
Upside: -17.56%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $220.75
Upside: -12.12%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $25.15
Upside: -0.60%